Ruti Aga Banned for Six Years: How One Forged Prescription Turned a Two-Year Sanction into Six

Ethiopian marathon runner Ruti Aga has been banned for six years by the Athletics Integrity Unit (AIU). The sanction is not the product of a single incident but the sum of two separate violations: two years for the presence of a prohibited substance in-competition, and four years for tampering with the anti-doping process. According to the AIU statement issued on Thursday, the periods run consecutively for a total of six years, counted from 10 September — the date her provisional suspension began. For the 32-year-old Aga, the practical consequence is that the 2028 Olympic cycle is closed to her entirely, and the remainder of her competitive career will be served inside the ban. The case begins at a half marathon in China in March, which Aga won. A sample taken after the race returned an adverse finding for methylprednisolone. That is the competition now inside the scope of the AIU's action, although the statement does not explicitly say whether the result and prize money have been annulled. Standard AIU practice is automatic disqualification of the competition at which the sample was collected, so it is reasonable to assume the win and its earnings are gone — but that is inference, not confirmed fact. Aga's explanation was that she had a knee injury and was given the medication as treatment. That is where the problem starts. The 'doctor' who wrote the prescription turned out to be a family member with no medical registration, who claimed to have used 'an old prescription pad from a former workplace.' The clinic named on the document did not exist. In other words, this became a case about documentary fraud rather than about doping — and that is precisely why two years became six. There is a technical confusion here that has to be corrected, because the legal architecture of the entire case rests on it. Methylprednisolone has been described in several reports as a 'prohibited steroid' and as something WADA 'classes as performance enhancing.' That description is both incomplete and misleading. Methylprednisolone is not an anabolic steroid; it is a glucocorticoid, class S9 on the WADA Prohibited List. Under the current List, S9 glucocorticoids are prohibited in-competition only, and only when administered by injection, orally or rectally. That distinction is decisive not for the pharmacology of sanctioning but for the strategy of a defence. The direct implication is that a therapeutic knee injection is entirely legal out-of-competition. It becomes a violation only if residues are still present in a sample taken in-competition. Aga therefore had a legitimate and technically strong defence available: a clear account of the date of the injection, the route of administration and the medical necessity. In road racing the testing window opens at 23:59 the day before the race, so an injection given days earlier can still be caught. That is a technical detail, but it does not make a defence impossible. With real medical records, the case might never have existed. The forged-prescription chain contains three independent verification failures. First, the 'doctor' who issued it was not a registered physician and was a family member. Second, the clinic named on the document did not exist — or more precisely, the institution whose name was used explicitly disowned the document. Third, the 'old prescription pad' argument is itself an admission that the document was produced through an unauthorised channel. Not one verification passed. This is not a clerical error; it points to a deliberate effort, which is why it was treated as an aggravating rather than a mitigating fact. Now the arithmetic. Two years for presence, four years for tampering. Under the WADA Code the standard tampering sanction is four years, and this matches exactly. A two-year period is common in 'Specified Substance' cases where intent is not established. Had the athlete proved 'No Significant Fault,' the period could have been reduced — potentially below two years. The panel did not do so. It found the presence violation proven, did not treat intent as aggravating, but refused relief. The four-year tampering sanction was applied in full. There is a paradox here that cannot be ignored. A forged document is itself circumstantial evidence of an intent to conceal. Logically it could have been treated as aggravating the presence sanction. The panel did not do that — it kept the two violations separate and added them. That approach is legally coherent, but its practical meaning is that the tampering charge destroyed the only legitimate explanation the athlete still had. The dating of the ban also needs clarity. Counting from 10 September does not mean the athlete received a concession. Time served under provisional suspension is credited against the sanction; the period she has already spent on the sidelines simply counts as part of the ban. There is no real-world benefit. It is a procedural adjustment, not a reduction. On the career record, Aga's standing is beyond doubt. She won the 2026 Tokyo Marathon — a World Marathon Majors title and the peak of her career. She also has three second-place finishes at World Marathon Majors, which show that she was a genuinely world-class marathoner in the 2:18–2:20 range, not a one-season phenomenon. The March race at the centre of the case took place in a later year; absent a finding of earlier use, results before that date — including the 2026 Tokyo win — are not automatically annulled. The AIU statement does not specify the scope of disqualification. But age is a hard fact. A six-year ban at 32 means a return at roughly 38. Ethiopian women's marathon depth is such that selecting a 38-year-old with a doping record is not even a theoretical proposition. The ban is six years on paper; in practice it is career-terminal. This is where the real significance of the story lies — the knee injury and the medical system behind it. An intra-articular methylprednisolone injection is standard sports-medicine practice in distance runners. Chronic knee pathology is a known load-bearing failure mode in high-volume marathoners. That does not make the explanation automatically credible — it means a defence existed and could have been proven with documents. The real question is why it was not. The answer is probably structural. An athlete without a credentialed team physician, without any Therapeutic Use Exemption (TUE) infrastructure, and whose medical support runs through informal networks will, in a crisis, choose the easy document over the correct one. The TUE framework exists precisely for this. If the knee treatment was genuinely necessary, there were two paths: obtain a TUE, or keep the route and timing consistent with WADA rules. Neither appears in the evidence. And if the treatment was real, why manufacture a prescription at all? That question undermines the entire defence. The case also points to an economic pressure. Injured marathoners face an incentive to mask pain so that appearance-fee income continues; glucocorticoids are the cheapest and most available tool for that; and the surrounding medical network is informal. The forgery then looks less like a sudden lapse and more like the predictable output of an ungoverned system. Will this affect Ethiopia's competitive strength? Barely. The depth of Ethiopian women's marathon running is such that the removal of one 32-year-old changes nothing in national selection arithmetic, particularly when she holds no global championship medals. Her three Major second places were excellent commercial-tier results, not championship conversions. What is affected is not the competition but the governance regime. And that raises the question of China's label-race circuit. For East African marathoners, Chinese road races have been a lucrative, low-risk income tier between Majors — large appearance fees, relatively few races. But that same tier is now the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are colliding in the same races. The direct consequence is that results at this level will be scrutinised more closely. The bigger structural signal is that the AIU's enforcement frontier has shifted from 'detection' to 'document verification.' When an athlete or entourage offers a false or altered explanation after an initial violation, the case escalates sharply. Aga's case is not an outlier; it appears to belong to a family of East African road-racing cases in which an initial substance violation is compounded by a fabricated explanation. That pattern should be noted with caution, because every case has its own details. An appeal is theoretically open — the Court of Arbitration for Sport typically offers a window of about 21 days after the reasoned decision. But the forgery finding is document-based, and document-based findings are hard to overturn. There is another risk that should not be ignored: document forgery can travel beyond the AIU's jurisdiction into national legal process. The statement says nothing about this, but the possibility remains. Now the part that is not in the report and must remain inference. The year of the March race and of the ban's start is not stated; phrases such as 'provisionally suspended since 10 September' and 'statement on Thursday' imply the current year. Annulment of the race result and prize money is highly likely but not confirmed in writing. The race time, splits and field quality are also absent — so any judgment about that performance would be speculation. Nor is it clear whether an agent or management team member was investigated; the statement names only the family member. One thing is certain amid all this: this is less a doping story than a story about the failure of medical governance. A legitimate treatment — a glucocorticoid injection into the knee — had a clear winning path if the timing and route had been correct and the records real. The forged document closed that path. A two-year sanction became a four-year tampering sanction, and the career of a former Major champion at 32 is effectively over. The substance did not deliver this ban. The paperwork did.